论文部分内容阅读
目的:鉴定发热伴血小板减少综合征病毒的CD8n + T细胞表位，为了解抗病毒免疫机制和疫苗设计提供参考。n 方法:基于生物信息学方法在SFTSV非结构蛋白中预测潜在表位，利用酶联免疫斑点吸附试验、胞内因子染色、四聚体染色验证表位的免疫原性，体外复性试验验证表位与人白细胞分化抗原的结合力。结果:NS-3多肽能刺激特异性CD8n + T分泌多种细胞因子，且诱导CD107a表达水平升高。康复病例中检测到NS-3表位特异性CD8n + T细胞分群。NS-3与HLA-A*3001能稳定结合。n 结论:从SFTSV的NS蛋白中鉴定到首个人源HLA-A*3001限制性CD8n + T细胞表位NS-3，为疫苗开发提供依据。n “,”Objective:To identify the CD8n + T cell epitope of severe fever with thrombocytopenia syndrome virus (SFTSV), so as to understand the mechanism of antiviral immunity and provide reference for vaccine development.n Methods:Based on bioinformatics method, potential epitopes in nonstructural protein were predicted. The immunogenicity of epitope was verified by enzyme-linked immunospot assay (ELISPOT), intracellular cytokine staining, tetramer staining. The binding ability of epitope to human leukocyte differentiation antigen was verified by n in vitro renaturation.n Results:The NS-3 peptide stimulated specific CD8n + T cells to secrete a variety of cytokines, and elevated the expression of CD107a. NS-3 epitope specific CD8n + T cell subsets were detected in recovered patient. The NS-3 epitope could bind stably to HLA-A*3001.n Conclusions:The first human HLA-A*3001 restricted CD8n + T cell epitope NS-3 was identified from the NS protein of SFTSV. This provides a basis for vaccine development.n